key: cord-0021307-de2yiu30
authors: Hollis, Chris; Hall, Charlotte L; Jones, Rebecca; Marston, Louise; Novere, Marie Le; Hunter, Rachael; Brown, Beverley J; Sanderson, Charlotte; Andrén, Per; Bennett, Sophie D; Chamberlain, Liam R; Davies, E Bethan; Evans, Amber; Kouzoupi, Natalia; McKenzie, Caitlin; Heyman, Isobel; Khan, Kareem; Kilgariff, Joseph; Glazebrook, Cristine; Mataix-Cols, David; Murphy, Tara; Serlachius, Eva; Murray, Elizabeth
title: Therapist-supported online remote behavioural intervention for tics in children and adolescents in England (ORBIT): a multicentre, parallel group, single-blind, randomised controlled trial
date: 2021-10-03
journal: Lancet Psychiatry
DOI: 10.1016/s2215-0366(21)00235-2
sha: 8e433392259960c076a025dc7048ac156a91798c
doc_id: 21307
cord_uid: de2yiu30

BACKGROUND: Exposure and Response Prevention (ERP) is a form of behavioural therapy for tics; however, its effectiveness remains uncertain. We aimed to evaluate the effectiveness of internet-delivered, therapist-supported, and parent-assisted ERP for treatment of tics in children and young people with Tourette syndrome or chronic tic disorder. METHODS: This multicentre, parallel group, single-blind, randomised controlled trial was conducted across two study sites in England. Participants were recruited via 16 patient identification centres, two study sites in England (Nottingham and London), or online self-referral. Eligible participants were aged 9–17 years, had Tourette syndrome or chronic tic disorder, had not received behavioural therapy for tics in the past 12 months or were about to start, and had a Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score (TTSS) of more than 15 or more than 10 if they had only motor or vocal tics. Patients were excluded if they had started or stopped medication for tics within the past 2 months; had current alcohol or substance dependence, psychosis, suicidality, anorexia nervosa, or suspected moderate to severe intellectual disability; or presented an immediate risk to self or others; or the parent or carer was unable to speak, read, or write in English. Eligible patients were randomly assigned (1:1) by masked outcome assessors to receive 10 weeks of online, remotely delivered, therapist-supported ERP or psychoeducation (active control). Outcome assessors, statisticians, health economists, the trial manager, and the chief investigator were masked to group allocation. Patients were not directly informed of their allocation, but this could be established from the content once treatment commenced and the patients were not, therefore, considered masked to treatment. The primary outcome was YGTSS-TTSS 3 months after randomisation, and analysis was done in all randomised patients for whom data were available for each timepoint and outcome. Safety analysis was by intention to treat. Longer term follow-up is ongoing. This trial is registered with ISRCTN (ISRCTN70758207) and ClinicalTrials.gov (NCT03483493). FINDINGS: Between May 8, 2018, and Sept 30, 2019, we assessed 445 candidates for inclusion in the study. 221 potential participants were excluded (90 did not meet inclusion criteria, 84 declined to participate, and 47 unable to contact family). 224 participants were enrolled and randomly assigned to ERP (n=112) or psychoeducation (n=112). The enrolled patients were mostly male (n=177; 79%) and of White ethnicity (n=195; 87%). 11 patients were lost to follow-up 3 months after randomisation in the ERP group, compared with 12 patients in the psychoeducation group. Mean YGTSS-TTSS at 3 months after randomisation was 23·9 (SD 8·2) in the ERP group and 26·8 (7·3) in the psychoeducation group. The mean total decrease in YGTSS-TTSS at 3 months was 4·5 (16%, SD 1·1) in the ERP group versus 1·6 (6%, 1·0) in the psychoeducation group. The estimated mean difference in YGTSS-TTSS change between the groups adjusted for baseline and site was –2·29 points (95% CI –3·86 to –0·71) in favour of ERP, with an effect size of –0·31 (95% CI –0·52 to –0·10). Two serious adverse events occurred (one collapse and one tic attack), both in the psychoeducation group, neither of which were related to study treatment. INTERPRETATION: ERP is an effective behavioural therapy for tics. Remotely delivered, online ERP with minimal therapist contact time represents an efficient public mental health approach to improve access to behavioural therapy for tics in children and adolescents. FUNDING: National Institute for Health Research and Health and Technology Assessment.

The primary outcome for the ORBIT Trial is the severity of tics as measured by the total tic severity score (TTSS; 0-50) on the Yale Global Tic Severity Scale (YGTSS; 1 ). The YGTSS is administered by a blinded outcomeassessor as an investigator-based semi-structured interview focussing on motor and vocal tic frequency, severity and tic related impairment over the previous week. The YGTSS symptom checklist lists 46 tic disorder symptoms, including 12 simple motor tics (e.g., eye blinking), 19 complex motor tics (e.g., facial expressions), seven simple vocal tics (e.g., coughing), and eight complex vocal tics (e.g., words), with four of these items designated on the instrument as "other" symptoms. The YGTSS generates a total tic severity score (0-50) and an impairment score (0-50).

Five index scores are obtained: Total Motor Tic Score, Total Phonic Tic Score, Total Tic Score, Overall Impairment Rating, and Global Severity Score. The Total Motor Tic Score is derived by adding the five items pertaining to motor tics (range: 0-25); the Total Phonic Tic Score is derived by adding the five items pertaining to phonic tics (range: 0-25); the Total Tic Score is derived by adding the Total Motor Tic Score and the Total Phonic Tic Score; and the Overall Impairment Rating is rated on a 50-point scale anchored by 0 (no impairment) and 50 (severe impairment). A Global Severity Score (range: 0-100) is derived by summing the Total Motor Tic Score, Total Phonic Tic Score, and Overall Impairment Rating. The Total Tic Severity Score (0 -50) is the primary outcome.

For ORBIT, rater training of our YGTSS assessors will consist of the following steps: 1) Researchers training on the YGTSS will be supervised by Dr Tara Murphy (TM) the Expert Rater (ER).

2) Training will consist of reading TM's slides on YGTSS which include the background and basic instructions for using the YGTSS.

3) They are also required to read the pivotal Leckman et al. (1988) paper.

Assessors are asked to view at least 3 pre-recorded YGTSS assessment sessions. They will be asked to rate these, however this will be solely for training purposes, with discussions afterwards and scores will not be used to calculate reliability or agreement. Assessors are encouraged to make a list of any questions/queries and rationale behind their decision making. 5) They then discuss their scores on this with TM. 6 ) Assessors then undergo a live test score with TM (i.e. the score a dummy patient) and also shadow a live assessment of YGTSS with an experienced assessor and score the patient. These scores are then discussed with TM/experienced assessor to compare scores and discuss the rationale behind the scoring.

7) The next step will be a testing phase where 3 different YGTSS assessments will be used against an ER to determine the extent of agreement with the ER. 8) In line with the methodology reported by 2 the raters have to be within 15% of the ER for the Total Motor Tic score, the Total Vocal Tic score and the Total Tic Score on the 3 recordings.

9) The 15% will always be rounded up in cases where 15% of a score results in a score which is not a whole integer (i.e. 15% of 25 = 3.75 points, this would be rounded up to 4 points). The 15% can be in either direction of the score.

10) Assessors who do not meet the criteria will be given additional training and asked to score the recordings again until the specified agreement criteria are met.

11) The assessors agreement with the ER will be assessed every 6 months during the trial. Up to a total of 4 new YGTSS assessment videos will be used to check agreement at follow-up (i.e. after initial agreement within the specified range has been established). The videos will be recordings from YGTSS conducted on ORBIT patients at baseline or follow-up assessments. Each of the trial assessors will submit at least one video.

12) If any assessors falls outside this 15% agreement with the ER, they will be required to engage in further training, as and when this is appropriate during the trial.

13) Assessors also participate in monthly conference calls with the ER and trial manager. These calls provided a forum for discussing cases and developing a common approach to conducting assessments across sites. Additional reviewing of videos and discussion with the assessors about scoring will be provided by the ER via email on an ad hoc basis. The ER will keep a record of these supervision meetings. Note. ER = expert rater. R=researcher. TTS = total tic score. 15low = 15% lowest threshold. 15high = 15% highest threshold. Motor total = total motor tic score. Vocal total = total vocal tic score. Scores in bold are outside the threshold

Adverse events (AEs) and serious adverse events (SAEs) are recorded until the 6-month follow-up and may be reported through various sources in this study:

1) AE's/SAEs may be reported to the therapist or the researcher through communication with the participants. 2) AE's are also recoded through completion of the Mood & Feelings Questionnaire (MFQ), completed at baseline, 5weeks, and 3-6-12-18-months. Any total score >29 at the follow-ups (5weeks, 3months, 6months) or any score greater than 0 on items 16, 17 and 19 (indicators of suicidal ideation) at followups (5weeks, 3months, 6months) is recorded as an AE if it is greater than their baseline score. The MFQ is completed by the young person. 3) AE's are also recorded through the side-effects questionnaire completed at baseline, 5weeks, 3 and 6months. A score on any item that is equal-to-or-greater-than 2 ("about half the time") and greater than their baseline score is recorded as an AE. The side-effects questionnaire is completed by the parent/carer.

AEs are recorded by the trial manager and researchers. Seriousness is assessed in the first instance by the trial manager and the researchers who reported the AE, if there are any concerns or doubts with seriousness or relation to the intervention the Chief Investigator (CI) is informed. The CI is informed of all SAEs and is responsibility for making final categorisation.

The protocol defines an SAE as any untoward occurrence that:

• Results in death,

• Is life-threatening,

• Requires hospitalisation or prolongation of existing hospitalisation, • Results in persistent or significant disability or incapacity, or • Consists of a congenital anomaly or birth defect • Is otherwise considered medically significant by the investigator

The following are a list of adverse events listed as 'expected' in the protocol.

-Increased anger/outbursts/disruptive behaviour -Increased irritability -Increased depressed mood -Increased anxiety/stress -Increased tics -Increased tiredness/fatigue -Headaches -Increased/decreased sleep 

The aim of the economic evaluation is to calculate the cost of online-delivered, therapist-supported ERP compared with online education from a health and social care cost perspective over 6 months. This will be reported alongside the difference in Total Tic Severity Score (TTSS) on the Yale Global Tic Severity Scale (YGTSS) to calculate the mean incremental cost per point reduction in YGTSS-TTSS.

Secondary aims are to:

• Report descriptive statistics for resource use;

• Calculate the incremental cost per point difference in YGTSS-TTSS from a wider cost perspective.

• Report descriptive statistics for utility tariffs calculated using responses to the CHU-9D over 6 months to inform the design of a decision analytical model of online ERP vs online education at 18 months.

• Mean fixed cost per participant of the web-based platform for those in the ERP arm • Mean cost per participant of variable platform costs and therapist support by trial arm • Mean total health care cost per participant over 6 months by trial arm • Mean incremental cost per point decrease in YGTSS-TTSS of Online ERP compared with Online Education and 95% confidence intervals • Cost-effectiveness plane • Cost-effectiveness acceptability curve • Mean utility per participant at baseline, 3 and 6 months by trial arm

The cost of the platform is split into a fixed cost per participant and a variable cost based on platform use.

A yearly cost of the platform was provided by the Swedish team in SEK. This was translated into GBP using the exchange rate at the time of the analysis (September 2020). This cost is divided by the number of participants using the platform to a conservative estimate of the fixed cost per participant: it is likely that there will be a higher caseload of people using the platform if it were to be rolled out and hence it is likely the cost per patient would be less.

Every time a participant logs into the BiP platform they are sent a text message. To account for this an average of the cost of sending a text with different UK network providers has been calculated. This has then been multiplied by the number of log ins to the platform by participants and their parent/carer.

The cost of therapist support is also broken down into a fixed and variable cost.

The fixed cost of therapist support is made up of the cost of training and supervision for the therapists. Most of the therapists were trained in supervision which occurred every week over the course of the intervention for an hour. The hourly cost of therapists and those providing supervision is used to calculate the total cost of supervision and training. This cost is also divided by the number of participants using the platform in order to provide an average fixed cost of therapist support per participant. It is also likely that this is a conservative estimate (the true cost per patient is likely to be less as the number of patients per therapist may be higher).

Total therapist time per participant is collected as part of the platform. This is broken down into therapist time for the child, parent 1 and parent 2, and phone time with the therapist for the child, parents and parents and child together. A patient level variable cost of therapist support is calculated for each participant based on therapist time reported and the grade of the therapist they are reported to have interacted with.

Health and social care resource use is collected using an adapted version of the Child and Adolescent Service Use Schedule (CA-SUS) developed in previous studies. 1, 2, 3 Resource use is collected on specialist tic services, contacts with professionals in the community, inpatient contacts, emergency contacts and medication use. The number of participants reporting each type of resource use are reported as a proportion of their trial arm as well as the average number of contacts for those that used the service.

The total cost of health and social care resource use is calculated using unit costs from the most recent Unit costs of Health and Social Care published by the personal Social Services Research unit (PSSRU) 4 and reference costs. Medication costs are calculated using the British National Formulary (BNF). Mean cost per participant in the ERP group versus the psychoeducation (active control) is reported as total mean cost per participant and by type of service at baseline and total at 6 months. The difference in costs at 6 months and 95% confidence intervals are calculated using a bias corrected bootstrapped regression adjusted for baseline and site. Costs are not discounted as the time horizon is less than one year.

Unit costs that were used in the analysis are reported in Table 1 . Where contacts occurred at home a ratio of direct to indirect time was applied based on the ratio of GP home visits to clinic visits. 4 Similarly, an average of the ratio from GP clinic contacts to GP phone contacts and nurse clinic contacts to nurse phone contacts was applied to adapt unit costs to phone contacts when the individual cost of phone contacts was not available. 

Wider societal costs include out of pocket costs, the cost of education support, voluntary services and the cost of days off from school. We report wider service use and days off school by arm. When reporting days off from school we report total days off as well as the number of days off which participants attributed as being related to Tourette syndrome.

Out of pocket costs are calculated using the amount reported by parents in the CA-SUS. Wider service use is calculated using online sources shown in Table 4 . The cost of days off from school are calculated using a human capital approach based on the cost of childcare for each day a participant has reported taking off school. 

Utility tariffs are calculated from responses to the CHU-9D, 5 a child specific patient reported outcome measure validated for use in the calculation of Quality Adjusted Life Years (QALYs) and applying the algorithm developed by Stevens. 6 The CHU-9D was completed as a patient reported outcome by the child and a proxy reported outcome asking about the child by a parent/carer at baseline, 3 and 6 months.

It is likely that the time-horizon of the trial data of 6 months is of insufficient duration to capture the full benefit of the intervention, whereas a more appropriate time horizon for a full economic evaluation would be a minimum of 18 months. As a result, we only report descriptive statistics for utilities to provide information of the potential suitability of the CHU-9D in a decision model using 18-month data and not for the calculation of QALYs.

Analyses were pre-specified in a health economics analysis plan (HEAP).

We have reported complete case descriptive statistics for the percentage of participants that used each type of resource and mean number of contacts for the participants that used them. The mean difference in costs and utilities, 95% confidence interval for each resource use type was calculated using regression analysis adjusting for baseline costs, with site as a covariate and bias corrected bootstrapping with 1,000 iterations for complete cases (complete resource use at baseline, 3-and 6-month follow-up).

We assumed data was missing at random (MAR). Predictors of missingness were explored, with site identified as the only predictor of missingness. In line with the statistical analysis of the primary outcome we have conducted a complete case analysis adjusting for predictors of missingness.

We explore the mean incremental cost per point reduction in YGTSS-TTSS between the ERP arm and psychoeducation arm from the health and social care cost perspective at 6 months. Costs include total healthcare resource use per participant and variable costs per participant for both trial arms. For the intervention arm, costs include the cost for the platform, therapist time, supervision and training. For the psychoeducation arm we do not include any platform costs, assuming that this information would be available as standard. The incremental cost per point reduction in YGTSS-TTSS was calculated using seemingly unrelated regression (SUR; Stata command SUREG) to account for any potential correlation between costs and outcomes.

The adjusted, bootstrapped, SUR YGTSS-TTSS and costs data were used to calculate the probability that the ERP intervention is cost-effective compared to the psychoeducation for a range of cost-effectiveness threshold values. A cost-effectiveness plane of the bootstrapped results is also reported.

Sensitivity analyses were conducted to explore the impact of different assumptions regarding the cost the intervention on the potential cost-effectiveness of the ERP intervention compared with the psychoeducation arm. Two assumptions were changed:

• Applying a licence fee per participant instead of a fixed cost per year based on a UK iCBT digital intervention. 7 We apply different licence fees starting at £25 to explore how this impacts the probability of cost-effectiveness. • Assuming fortnightly supervision instead of weekly supervision of therapists delivering the intervention.

Fixed cost: Cost per year in SEK 96000

Cost per year in GBP September 2020 8494

Fixed cost of platform per participant GBP (Number of participants using platform = 222) 38

Variable costs: 

Fixed cost: For variable therapist support costs, the mean cost per patient was £5•03 higher (95% CI £0•88 to £9•97) for ERP compared with psychoeducation. The mean cost of therapist support for the intervention was £71•03.

In total, the mean cost of the intervention per participant was £110. Table 9 reports the mean number of contacts and SD for those who have used the service for specialist tic services.

Other service use and medication use are reported in tables 10 and 11. There was no significant difference in costs between the two group with a mean per patient difference in total resource use cost at 6 months of £63 (95% CI -£158 to £284) for the ERP arm compared with the psychoeducation (see Table 12 ). Table 13 reports the proportion of participants in each arm that had contacts with education support services and voluntary services at baseline and over the following 6 months. The proportion of participants using these services was similar in both groups and there was no significant difference between the groups in terms of the cost of these services (Table 15 ). The number of days taken off school by the participants in both groups is shown in Table 14 . Around 20% of participants reported taking days off that were related to Tourette syndrome symptoms or healthcare appointments due to the illness. Of those who reported taking days of due to the illness, there was no significant difference in the number of days taken off between groups. The cost of total days off school is reported in Table  15 . There was no significant difference in costs. Total wider costs were £117•07 higher on average for those in the intervention group (95% CI -£205•95 to £440•09). Once total healthcare costs were accounted for the difference was £203•16 (95% CI -£241•03 to £647•34). The difference in costs was not significant in either case.

The follow up rate for the CHU-9D is lower than for the CA-SUS as this was collected using a different method to the primary outcome. At 6 months, for the child completed CHU-9D, utility scores were 0•046 (95% CI 0•013 to 0•080) higher for those in the ERP group compared to those in the psychoeducation group (Table 16) . There was no statistically significant difference between arms for the parent completed CHU-9D (0•010 95% CI -0•023 to 0•043). 

The incremental mean cost per patient of the ERP compared to the psychoeducation was £159 (95% CI -£53 to £370), with a mean of -2•65 points reduction on the YGTSS-TTSS (95% CI -4•55 to -0•74), with an incremental cost per reduction in YGTSS-TTSS (YGTSS-TTSS multiplied by -1) of £60 from a health and social care costperspective. There is a 99% probability that the ERP intervention is cost-effective compared with the psychoeducation for cost-effectiveness thresholds greater than £400, with a 79% probability that the ERP is costeffective compared to psychoeducation at a £100 threshold.

From a wider cost perspective, the incremental cost per point reduction in YGTSS-TTSS was £48•58, with a 95% probability of being cost effective compared with the psychoeducation control at cost-effectiveness threshold of £400.

In order to explore how different costing models for the platform impact the cost-effectiveness of the intervention we applied a licence fee starting at £25 per participant and increasing by £10 increments until £165. At a threshold value of £100 per point reduction in YGTSS-TTSS the probability of cost-effectiveness falls below 50% at a licence fee per participant of £145 or more. The probability that the ERP intervention is costeffective compared to the psychoeducation at a cost-effectiveness threshold of £400 when applying the £145 licence fee is 97%.

As therapists were trained during supervision, it is feasible to assume that once fully trained and familiar with the delivery of the intervention only fortnightly supervision would be necessary. When applying fortnightly supervision, the fixed cost of the intervention falls from £104 to £71. This results in an incremental costeffectiveness ratio of £54 per point reduction in YGTSS-TTSS and probability of 82% of being cost-effective compared with the psychoeducation at a threshold of £100. 

Based on our exploratory economic evaluation, the therapist supported online remote behavioural intervention for tics cost £159 more on average per patient than online education, with the majority of the cost accounted for by the additional cost of the intervention. The mean additional cost per patient of the platform and therapist time including training and support was £110; this could be as low as £77 per participant if a move to fortnightly supervision is assumed. There was no evidence that the intervention had a significant impact on health and social care costs at 6 months compared to online education.

There was a statistically significant difference in favour of the intervention for the child completed CHU-9D, but not the proxy parent completed questionnaire, with the child completed version better reflecting the results for the primary outcome (YGTSS-TTSS). This mirrors research by Storch et al. 8 which compared tic severity to child and parent reported quality of life. They found that parent reported quality of life was weakly correlated to tic severity and that parent and child reported quality of life did not correlate as well in older children (>11 years).

This analysis is exploratory only to provide initial information on the potential cost of the ERP intervention compared to the psychoeducation and any anticipated impacts on costs and QALYs. The time horizon of the analysis is too short to conduct a full economic evaluation of the cost per QALY gained of the intervention compared to the psychoeducation given the 6-month follow-up period, with a maximum of 0•5 QALYs available. Instead, a full economic evaluation of the ERP intervention compared to the psychoeducation will be conducted using data from the 18-month trial follow-up. This will include a decision model projecting changes in YGTSS-TTSS into the future and mapping CHU-9D to the YGTSS-TTSS to calculate QALYs. It appears that this will be feasible and meaningful based on our initial results reported above given that the child completed CHU-9D and the YGTSS-TTSS seem to both be showing that the intervention results in better outcomes than online education. Our current finding that the mean incremental cost per point reduction in the YGTSS-TTSS is £60 is for illustrative purposes only given that it is not clear what the threshold for cost-effectiveness is for a point change in YGTSS-TTSS. There is a very high probability though that ERP is cost-effective compared to online education for very low thresholds of cost-effectiveness (>£100 per point reduction in YGTSS-TTSS). Further work will also need to be conducted on whether online education is the only comparator to the online behavioural intervention, as faceto-face therapy may also need to be included as a comparator in the decision model, with the view that it may be as effective, or potentially more effective than the online intervention, but likely for a significantly greater cost. The effectiveness and cost of face-to-face therapy will be obtained from the literature. 

Cost-effectiveness analysis of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves: Results of a randomised controlled trial

Randomised comparison of the effectiveness and costs of community and hospital based mental health services for children with behavioural disorders

Mental health provision for young offenders: Service use and cost

Unit Costs of Health and Social Care

The validity of the Child Health Utility instrument (CHU9D) as a routine outcome measure for use in child and adolescent mental health services

Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation

A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. npj Digit Med

Quality of life in youth with Tourette's syndrome and chronic tic disorder